Research Centre

临床研究中心

多年来,寶康醫院已成为马来西亚一家著名的癌症专科医院,也在东南亚地区开创立体定向放射外科(电脑刀)治疗,同时也提供其他形式的癌症治疗,如放射治疗、化疗、免疫治疗和标靶治疗。在寶康醫院,我们的肿瘤科医生进行实证护理,并根据每个病人的疾病状况,制定最有效的治疗方案。

为了响应实证护理的临床研究需求,我们的肿瘤科团队积极参与并促进国际临床试验和研究,以便为患者开发更好的肿瘤治疗。我们的临床研究活动始于2008年,目前仍在持续进行,因为我们坚信,我们所参与的临床试验将提供最新的治疗知识,以及独一无二的最新突破性治疗。

尽管研究对治疗进展非常重要,但我们会确保参与临床试验的患者的权利、安全和健康始终是最重要的。我们所有的临床研究已获得马来西亚卫生部医疗和研究伦理委员会的批准外,我们还遵守当地和国际良好临床实践(GCP)标准,以保障参与试验的患者的伦理利益。

除了肿瘤学临床试验,来自其他卓越中心的顾问也通过发表研究论文为临床专业做出了重大贡献。以下是我们的顾问发表的研究成果(摘要、研究论文、海报等):

NoClinical TrialStatus
1A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy In Treatment Naive Subjects With PD-L1 Positive Advanced Or Metastatic Non-Small Cell Lung Cancer (Keynote 042)Active
2A Phase Ib/II Multicenter, Randomized, Open Label Trial To Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy As Second-line Treatment In Subjects with MET Positive, Locally Advanced Or Metastatic Nonsmall Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance To Prior EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) TherapyActive
3A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma PatientsActive
4Studies On Epigenetic Changes In Nasopharyngeal CancerActive
5Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer CareActive
6Healthcare Performance Measurement And Reporting For Breast Cancer Services In MalaysiaCompleted
7A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction AdenocarcinomaCompleted
8A Randomized, 3 Arm, Multicentre, Phase III Study To Evaluate The Efficacy And The Safety Of T-DM1 Combined With Pertuzumab Or T-DM1 Combined With Pertuzumab-Placebo (Blinded For Pertuzumab), Versus The Combination Of Trastuzumab Plus Taxane, As First Line Treatment In HER2- Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer (MBC)Completed
9A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.Completed
10An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC)Completed

Apart from oncology clinical trials, our consultants from other centres of excellence have also made substantial contributions to their clinical specialty with their published research. Below are the research publications (abstract, research papers, poster presentations, etc) produced by our consultants:

NoPublication TitleName of ConsultantType of Presentation
1Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical PhotographsDr Ong Chin TuanPoster
Find Consultant